Pembrolizumab for previously treated, microsatellite instability–high/mismatch repair–deficient advanced colorectal cancer: final analysis of KEYNOTE-164

微卫星不稳定性 彭布罗利珠单抗 结直肠癌 医学 DNA错配修复 癌症 肿瘤科 内科学 癌症研究 微卫星 生物 遗传学 免疫疗法 基因 等位基因
作者
Dung Thi Le,Luis Alberto Diaz,Tae Won Kim,Eric Van Cutsem,Ravit Geva,Dirk Jäger,Hiroki Hara,Matthew Burge,Bert H. O’Neil,Petr Kavan,Takayuki Yoshino,Rosine Guimbaud,Hiroya Taniguchi,Elena Élez,Salah-Eddin Al-Batran,Patrick McKay Boland,Yi Cui,Pierre Leconte,Patricia Maria Marinello,Thierry André
出处
期刊:European Journal of Cancer [Elsevier BV]
卷期号:186: 185-195 被引量:100
标识
DOI:10.1016/j.ejca.2023.02.016
摘要

Background Pembrolizumab demonstrated durable clinical benefit and manageable safety in previously treated advanced or metastatic microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) colorectal cancer (CRC) in the phase 2 KEYNOTE-164 study. Results from the final analysis are presented. Methods Eligible patients had unresectable or metastatic MSI-H/dMMR CRC and ≥2 prior systemic therapies (cohort A) or ≥1 prior systemic therapy (cohort B). Patients received pembrolizumab 200 mg intravenously every 3 weeks for ≤35 cycles. The primary end-point was objective response rate (ORR) assessed per Response Evaluation Criteria in Solid Tumors, version 1.1 by blinded independent central review. Secondary end-points included duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety and tolerability. Results Sixty-one patients in cohort A and 63 patients in cohort B were enroled; median follow-up was 62.2 months and 54.4 months, respectively. ORR was 32.8% (95% CI, 21.3%–46.0%) in cohort A and 34.9% (95% CI, 23.3%–48.0%) in cohort B. Median DOR was not reached (NR) in either cohort. Median PFS was 2.3 months (95% CI, 2.1–8.1) in cohort A and 4.1 months (95% CI, 2.1–18.9) in cohort B. Median OS was 31.4 months (95% CI, 21.4–58.0) in cohort A and 47.0 months (95% CI, 19.2–NR) in cohort B. No new safety signals were observed. Nine patients who initially responded experienced disease progression off therapy and received second-course pembrolizumab. Six patients (66.7%) completed an additional 17 cycles of pembrolizumab, and 2 patients achieved a partial response. Conclusions Pembrolizumab continued to show durable antitumor activity, prolonged OS, and manageable safety in patients with previously treated MSI-H/dMMR CRC. Clinical Trial Registry Information ClinicalTrials.gov, NCT02460198
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
本喵不怂完成签到,获得积分20
刚刚
领导范儿的应助被余子文采纳,获得10
1秒前
科研通AI6.2的应助被吱吱采纳,获得10
1秒前
1秒前
zhyzzz发布了新的文献求助10
1秒前
sunxiaojun发布了新的文献求助10
1秒前
温凉发布了新的文献求助10
1秒前
1秒前
4秒前
4秒前
慕青的应助被liugm采纳,获得10
4秒前
小二郎的应助被哇哇哇采纳,获得10
5秒前
th1e发布了新的文献求助10
5秒前
Philo完成签到,获得积分10
6秒前
听安发布了新的文献求助10
7秒前
7秒前
Forward发布了新的文献求助10
7秒前
8秒前
傲娇钢笔完成签到 ,获得积分10
8秒前
一只咸鱼完成签到 ,获得积分10
8秒前
开心的畅畅完成签到 ,获得积分10
9秒前
9秒前
酷波er的应助被hbuiio采纳,获得10
10秒前
cuipi发布了新的文献求助10
10秒前
CipherSage的应助被Twinkle采纳,获得10
11秒前
香蕉觅云的应助被erdongsir采纳,获得10
11秒前
12秒前
张奕泽发布了新的文献求助10
12秒前
13秒前
小巧慕蕊完成签到,获得积分10
13秒前
Bryn_Wang完成签到,获得积分10
13秒前
13秒前
ZZG完成签到,获得积分10
13秒前
乐观期待完成签到,获得积分10
15秒前
无花果的应助被mingyu采纳,获得10
15秒前
zhyzzz完成签到,获得积分10
15秒前
烟花的应助被WLLLR采纳,获得10
16秒前
16秒前
17秒前
英吉利25发布了新的文献求助10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8189472
求助须知:如何正确求助?哪些是违规求助? 9576774
关于积分的说明 21849709
捐赠科研通 7787422
什么是DOI,文献DOI怎么找? 3435600
关于科研通互助平台的介绍 2559782
邀请新用户注册赠送积分活动 2482552